Perioperative Short-Term Glucocorticoids Do Not Increase Incidence of Complications after Total Joint Arthroplasty in Patients with Rheumatoid Arthritis

Abstract

Objectives: The safety and analgesic efficacy of perioperative glucocorticoids have been established for patients without rheumatoid arthritis. Therefore, our study aims to investigate whether similar benefits can be observed in patients with rheumatoid arthritis undergoing total joint arthroplasty. Specifically, we aim to explore the impact of perioperative glucocorticoid use on postoperative complications, opioid consumption, incidence of hypotension, hyperglycemia, 30-day mortality, and 90-day re-admission in this patient population.

Methods: Approval for the study protocol was obtained from the Medical Research Ethics Committee at Sichuan University, aligning with the principles outlined in the Declaration of Helsinki. We retrospectively analyzed a consecutive series of patients with rheumatoid arthritis who underwent total joint arthroplasty at our medical center between November 2009 and April 2021 and who were not on chronic glucocorticoid therapy before surgery. Those who received glucocorticoids at any time during hospitalization were compared to those who did not in terms of acute complications within 90 days after surgery as well as postoperative rescue opioid consumption, hypotension, and hyperglycemia during hospitalization. The two groups were also compared in terms of overall duration of hospitalization, all-cause mortality within 30 days, and readmission for any reason within 90 days. Continuous data were assessed for significance using the independent-samples t test. Categorical data were assessed using the Pearson chi-squared test.

Results: Of the 849 patients included in the analysis, 598 administered perioperative glucocorticoids and 251 did not. Prior to surgery, the two groups did not differ significantly in any clinicodemographic variable that we examined. The incidence of acute postoperative complications (2.3% vs. 4.0%, p = 0.187) and acute postoperative infection (2.0% vs. 2.8%, p = 0.482) was comparable between those who received perioperative glucocorticoids and those who did not, but the former group exhibited a significantly lower incidence of rescue opioid use (17.9% vs. 44.6%, p < 0.001) as well as significantly lower total rescue opioid consumption (4.7 ± 2.1 mg vs. 8.9 ± 4.6 mg, p < 0.001). However, the two groups showed similar incidences of postoperative hypotension, hyperglycemia, 30-day mortality, and 90-day re-admission.

Conclusion: Perioperative glucocorticoids may reduce the need for rescue opioids after total joint arthroplasty of rheumatoid arthritis patients, without increasing the incidence of acute complications, hypotension or hyperglycemia.

Keywords

arthroplasty / complication / glucocorticoids / opioids / pain / rheumatoid arthritis

References

[1] Karam JA, Schwenk ES, Parvizi J. An update on multimodal pain management after Total joint arthroplasty. J Bone Joint Surg Am. 2021; 103(17): 1652–1662.

[2] Chan PK, Chan TCW, Mak CYH, Chan THM, Chan SHW, Wong SSC, et al. Pain relief after Total Knee arthroplasty with intravenous and Periarticular corticosteroid: a randomized controlled trial. J Bone Joint Surg Am. 2023; 105(12): 924–932.

[3] Gasbjerg KS, Hägi-Pedersen D, Lunn TH, Laursen CC, Holmqvist M, Vinstrup L, et al. Effect of dexamethasone as an analgesic adjuvant to multimodal pain treatment after total knee arthroplasty: randomised clinical trial. BMJ (Clinical Research Ed). 2022; 376: e067325.

[4] Hannon CP, Fillingham YA, Mason JB, Sterling RS, Casambre FD, Verity TJ, et al. The efficacy and safety of corticosteroids in Total joint arthroplasty: a direct meta-analysis. J Arthroplasty. 2022; 37(10): 1898–1905.e7.

[5] Ruberto RA, Farah O, Lopez C, Hickernell T. Perioperative intravenous glucocorticoids in Total joint arthroplasty: a systematic review. J Am Acad Orthop Surg. 2023; 31(2): e94–e106.

[6] Lex JR, Edwards TC, Packer TW, Jones GG, Ravi B. Perioperative systemic dexamethasone reduces length of stay in Total joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials. J Arthroplasty. 2021; 36(3): 1168–1186.

[7] Wu L, Si H, Li M, Zeng Y, Wu Y, Liu Y, et al. The optimal dosage, route and timing of glucocorticoids administration for improving knee function, pain and inflammation in primary total knee arthroplasty: a systematic review and network meta-analysis of 34 randomized trials. Int J Surg. 2020; 82: 182–191.

[8] Goodman SM, Springer BD, Chen AF, Davis M, Fernandez DR, Figgie M, et al. 2022 American College of Rheumatology/American Association of hip and Knee Surgeons Guideline for the perioperative Management of Antirheumatic Medication in patients with rheumatic diseases undergoing elective Total hip or Total Knee arthroplasty. Arthritis & Rheumatology (Hoboken, NJ). 2022; 74(9): 1464–1473.

[9] George MD, Baker JF, Winthrop K, Alemao E, Chen L, Connolly S, et al. Risk of biologics and glucocorticoids in patients with rheumatoid arthritis undergoing arthroplasty: a cohort study. Ann Intern Med. 2019; 170(12): 825–836.

[10] Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001; 60(3): 214–217.

[11] Chukir T, Goodman SM, Tornberg H, Do H, Thomas C, Sigmund A, et al. Perioperative glucocorticoids in patients with rheumatoid arthritis having Total joint replacements: help or harm? ACR Open Rheumatology. 2021; 3(9): 654–659.

[12] Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria an American College of Rheumatology/European league against rheumatism Collaborative initiative. Arthritis Rheum. 2010; 62(9): 2569–2581.

[13] Backes JR, Bentley JC, Politi JR, Chambers BT. Dexamethasone reduces length of hospitalization and improves postoperative pain and nausea after Total joint arthroplasty a prospective, randomized controlled trial. J Arthroplasty. 2013; 28(8): 11–17.

[14] Richardson AB, Bala A, Wellman SS, Attarian DE, Bolognesi MP, Grant SA. Perioperative dexamethasone administration does not increase the incidence of postoperative infection in Total hip and Knee arthroplasty: a retrospective analysis. J Arthroplasty. 2016; 31(8): 1784–1787.

[15] Polderman JAW, Farhang-Razi V, van Dieren S, Kranke P, DeVries JH, Hollmann MW, et al. Adverse side-effects of dexamethasone in surgical patients—an abridged Cochrane systematic review. Anaesthesia. 2019; 74(7): 929–939.

[16] Jorgensen CC, Pitter FT, Kehlet H. Lundbeck Foundation Center for Fast-track Hip and Knee Replacement Collaborative Group. Safety aspects of preoperative high-dose glucocorticoid in primary total knee replacement. Br J Anaesth. 2017; 119(2): 267–275.

[17] Gasbjerg KS, Hagi-Pedersen D, Lunn TH, Laursen CC, Holmqvist M, Vinstrup LO, et al. Effect of dexamethasone as an analgesic adjuvant to multimodal pain treatment after total knee arthroplasty: randomised clinical trial. Bmj-British Medical J. 2022; 376:e067325.

[18] Xu H, Zhang S, Xie J, Lei Y, Cao G, Pei F. Multiple doses of perioperative dexamethasone further improve clinical outcomes after Total Knee arthroplasty: a prospective, randomized. Controlled Study the Journal of Arthroplasty. 2018; 33(11): 3448–3454.

[19] Wasfie T, Tabatabai A, Hedni R, Hollern L, Barber K, Shapiro B. Effect of intra-operative single dose of dexamethasone for control of post-operative nausea and vomiting on the control of glucose levels in diabetic patients. Am J Surg. 2018; 215(3): 488–490.

[20] Arraut J, Thomas J, Oakley CT, Schmicker T, Aggarwal VK, Schwarzkopf R, et al. Effects of dexamethasone on postoperative glycemic control in diabetic patients following primary Total joint arthroplasty: a retrospective cohort study. J Arthroplasty. 2023; 38(7 Suppl 2): S138–S144.e2.

[21] Nurok M, Cheng J, Romeo GR, Vecino SM, Fields KG, YaDeau JT. Dexamethasone and perioperative blood glucose in patients undergoing total joint arthroplasty: a retrospective study. J Clin Anesth. 2017; 37: 116–122.

[22] Friedman RJ, Schiff CF, Bromberg JS. Use of supplemental steroids in patients having orthopaedic operations. J Bone Joint Surg Am. 1995; 77(12): 1801–1806.

[23] Goodman SM, Springer BD, Chen AF, Davis M, Fernandez DR, Figgie M, et al. 2022 American College of Rheumatology/American Association of hip and Knee Surgeons Guideline for the perioperative Management of Antirheumatic Medication in patients with rheumatic diseases undergoing elective Total hip or Total Knee arthroplasty. Arthritis Care Res (Hoboken). 2022; 74(9): 1399–1408.

RIGHTS & PERMISSIONS

2024 The Author(s). Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.